Nothing Special   »   [go: up one dir, main page]

CY1121395T1 - Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6 - Google Patents

Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6

Info

Publication number
CY1121395T1
CY1121395T1 CY20191100008T CY191100008T CY1121395T1 CY 1121395 T1 CY1121395 T1 CY 1121395T1 CY 20191100008 T CY20191100008 T CY 20191100008T CY 191100008 T CY191100008 T CY 191100008T CY 1121395 T1 CY1121395 T1 CY 1121395T1
Authority
CY
Cyprus
Prior art keywords
gpr6
tetrahydropyridopyrazines
formers
toy
compounds
Prior art date
Application number
CY20191100008T
Other languages
English (en)
Inventor
Jason Brown
Stephen Hitchcock
Maria HOPKINS
Shota Kikuchi
Holger Monenschein
Holly REICHARD
Kristin SCHLEICHER
Hukai SUN
Todd MACKLIN
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52440811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121395(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1121395T1 publication Critical patent/CY1121395T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις του τύπου (I): οι οποίες είναι χρήσιμες ως διαμορφωτές του GPR6, φαρμακευτικές συνθέσεις αυτών, μεθόδους για αγωγή καταστάσεων συναφών με τον GPR6, διεργασίες για την παραγωγή των ενώσεων και ενδιαμέσων αυτών.
CY20191100008T 2013-12-20 2019-01-03 Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6 CY1121395T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361919661P 2013-12-20 2013-12-20
PCT/US2014/071543 WO2015095728A1 (en) 2013-12-20 2014-12-19 Tetrahydropyridopyrazines modulators of gpr6

Publications (1)

Publication Number Publication Date
CY1121395T1 true CY1121395T1 (el) 2020-05-29

Family

ID=52440811

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100008T CY1121395T1 (el) 2013-12-20 2019-01-03 Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6

Country Status (41)

Country Link
US (4) US9181249B2 (el)
EP (2) EP3453709A1 (el)
JP (1) JP6538697B2 (el)
KR (1) KR102441531B1 (el)
CN (2) CN105829309B (el)
AR (2) AR098872A1 (el)
AU (1) AU2014368992C1 (el)
BR (1) BR112016014020B1 (el)
CA (1) CA2934247C (el)
CL (1) CL2016001595A1 (el)
CR (1) CR20160321A (el)
CY (1) CY1121395T1 (el)
DK (1) DK3083620T3 (el)
DO (1) DOP2016000144A (el)
EA (1) EA032443B1 (el)
EC (1) ECSP16061758A (el)
ES (1) ES2702187T3 (el)
GE (1) GEP201706783B (el)
HR (1) HRP20182004T1 (el)
HU (1) HUE042443T2 (el)
IL (1) IL246177B (el)
JO (1) JO3466B1 (el)
LT (1) LT3083620T (el)
MA (1) MA39193B1 (el)
MX (1) MX2016008188A (el)
MY (1) MY177031A (el)
NZ (1) NZ721723A (el)
PE (1) PE20160751A1 (el)
PH (1) PH12016501192A1 (el)
PL (1) PL3083620T4 (el)
PT (1) PT3083620T (el)
RS (1) RS58092B1 (el)
SG (1) SG11201604921TA (el)
SI (1) SI3083620T1 (el)
TN (1) TN2016000244A1 (el)
TR (1) TR201900038T4 (el)
TW (2) TWI730937B (el)
UA (1) UA120427C2 (el)
UY (1) UY35908A (el)
WO (1) WO2015095728A1 (el)
ZA (1) ZA201604703B (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359634B (es) 2011-12-21 2018-10-03 Novira Therapeutics Inc Agentes antivirales contra la hepatitis b.
US9487526B2 (en) 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
NZ704748A (en) 2012-08-28 2018-06-29 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
PL2961732T3 (pl) 2013-02-28 2017-09-29 Janssen Sciences Ireland Uc Sulfamoilo-aryloamidy i ich stosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
MX366787B (es) 2013-05-17 2019-07-23 Janssen Sciences Ireland Uc Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b.
AP2015008968A0 (en) 2013-07-25 2015-12-31 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b
UA117261C2 (uk) 2013-10-23 2018-07-10 ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі Похідні карбоксаміду та їх застосування як медикаментів для лікування гепатиту b
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EP3102225B1 (en) 2014-02-05 2020-03-25 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
KR20160110419A (ko) 2014-02-06 2016-09-21 얀센 사이언시즈 아일랜드 유씨 술파모일피롤아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
WO2015123505A1 (en) * 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Pyridopyrazines modulators of gpr6
WO2016149581A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AU2016330964B2 (en) 2015-09-29 2021-04-01 Novira Therapeutics, Inc. Crystalline forms of a hepatitis B antiviral agent
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
JOP20180057A1 (ar) * 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
KR20200131816A (ko) 2018-03-14 2020-11-24 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 캡시드 조립 조절제 투약 요법
CA3127152A1 (en) 2019-02-22 2020-08-27 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
KR20220005549A (ko) 2019-05-06 2022-01-13 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유도성 질환의 치료에 유용한 아미드 유도체

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005302A1 (en) * 1994-08-11 1996-02-22 Takeda Chemical Industries, Ltd. G protein coupled receptor protein, production, and use thereof
MXPA01008618A (es) * 1999-02-26 2002-03-20 Arena Pharm Inc Moduladores de molecula pequena de receptor seis acoplado de proteina g.
WO2001070269A1 (fr) 2000-03-24 2001-09-27 Akzo Nobel N.V. Inhibiteurs de la croissance des keratinocytes et derives d'acide hydroxamique
WO2004038416A1 (en) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6)
US7388019B2 (en) 2003-01-31 2008-06-17 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
SE0400285D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
MEP23808A (en) * 2006-04-21 2010-06-10 Pfizer Prod Inc Pyridine[3,4-b]pyrazinones
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
US8145966B2 (en) 2007-06-05 2012-03-27 Astrium Limited Remote testing system and method
GB0710844D0 (en) 2007-06-06 2007-07-18 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
GB2449929A (en) 2007-06-08 2008-12-10 Snell & Wilcox Ltd Hierarchical spatial resolution building processes to fill holes in an interpolated image
CN102625804B (zh) 2009-06-12 2015-04-08 Abivax公司 用于治疗aids的化合物
WO2013087815A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof
WO2013087808A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin
WO2013169964A1 (en) 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9487526B2 (en) 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
FR2995937B1 (fr) 2012-09-21 2014-09-26 Exoes Ensemble de production d'electricite a moteur a pression de vapeur
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6

Also Published As

Publication number Publication date
EP3453709A1 (en) 2019-03-13
JP2017502027A (ja) 2017-01-19
NZ721723A (en) 2021-07-30
TWI730937B (zh) 2021-06-21
AU2014368992C1 (en) 2019-02-21
DOP2016000144A (es) 2016-08-15
US9181249B2 (en) 2015-11-10
ZA201604703B (en) 2018-11-28
US10077266B2 (en) 2018-09-18
ECSP16061758A (es) 2018-02-28
JP6538697B2 (ja) 2019-07-03
CN108658978A (zh) 2018-10-16
BR112016014020B1 (pt) 2023-02-28
US20180346464A1 (en) 2018-12-06
EP3083620A1 (en) 2016-10-26
TW202202497A (zh) 2022-01-16
EA032443B1 (ru) 2019-05-31
MA39193B1 (fr) 2018-04-30
PL3083620T3 (pl) 2019-09-30
TW201605854A (zh) 2016-02-16
CR20160321A (es) 2016-09-28
BR112016014020A2 (pt) 2017-08-08
AU2014368992B2 (en) 2018-09-13
CL2016001595A1 (es) 2017-01-13
IL246177A0 (en) 2016-08-02
SG11201604921TA (en) 2016-07-28
US9708313B2 (en) 2017-07-18
PH12016501192B1 (en) 2016-08-15
US10738046B2 (en) 2020-08-11
RS58092B1 (sr) 2019-02-28
KR20160099705A (ko) 2016-08-22
SI3083620T1 (sl) 2019-02-28
EA201691272A1 (ru) 2017-05-31
AR098872A1 (es) 2016-06-22
GEP201706783B (en) 2017-11-27
HUE042443T2 (hu) 2019-06-28
WO2015095728A1 (en) 2015-06-25
TWI809395B (zh) 2023-07-21
TR201900038T4 (tr) 2019-01-21
LT3083620T (lt) 2019-02-11
TN2016000244A1 (en) 2017-10-06
US20160031881A1 (en) 2016-02-04
PT3083620T (pt) 2019-01-17
CA2934247A1 (en) 2015-06-25
PE20160751A1 (es) 2016-08-01
EP3083620B1 (en) 2018-10-03
ES2702187T3 (es) 2019-02-27
HRP20182004T1 (hr) 2019-02-08
PL3083620T4 (pl) 2019-09-30
UA120427C2 (uk) 2019-12-10
KR102441531B1 (ko) 2022-09-07
CN105829309A (zh) 2016-08-03
MY177031A (en) 2020-09-02
CN105829309B (zh) 2018-05-15
DK3083620T3 (en) 2019-01-14
CA2934247C (en) 2023-01-17
US20170283414A1 (en) 2017-10-05
UY35908A (es) 2015-07-31
IL246177B (en) 2019-11-28
JO3466B1 (ar) 2020-07-05
BR112016014020A8 (pt) 2018-01-30
US20150175602A1 (en) 2015-06-25
PH12016501192A1 (en) 2016-08-15
AR129635A2 (es) 2024-09-11
AU2014368992A1 (en) 2016-07-07
MX2016008188A (es) 2016-09-29
MA39193A1 (fr) 2017-06-30

Similar Documents

Publication Publication Date Title
CY1121395T1 (el) Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6
CY1120029T1 (el) Παραγωγα 6-(5-υδροξυ-1η-πυραζολ-1-υλ) νικοτιναμιδιου και χρηση τους ως αναστολεις phd
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CY1119105T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
CY1123417T1 (el) Παραγωγα τετρα�δροϊσοκινολινης
CY1118860T1 (el) Νεα διαζασπειροκυκλοαλκανια και αζασπειροκυκλοαλκανια
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
CO7141403A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CO7141404A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
CY1124929T1 (el) 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινες ως ρυθμιστες του gpr139
BR112015004111A2 (pt) novos derivados bicíclicos
EA201890373A1 (ru) Пиридиновые соединения, пригодные для борьбы с фитопатогенными грибами
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
CY1125143T1 (el) Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων
CY1120763T1 (el) Νεες ενωσεις σουλφονυλαμινοβενζαμιδιου
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
PH12016501613B1 (en) Pyrazines modulators of gpr6
CO7141402A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CY1121313T1 (el) Φαρμακευτικη διεργασια και ενδιαμεσα
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
CY1120153T1 (el) Μεθοδος για την παρασκευη 19-νορπρεγκν-4-εν-3,20-διονο-17.αλφα.-ολης (gestonorone) και ενδιαμεσων αυτης
PL411140A1 (pl) Nowe pochodne 1-(piperazyn-1-ylo)-9, 10-antrachinonu funkcjonalizowane wybranymi aminokwasami i sposób ich otrzymywania
PL408052A1 (pl) Nowa pochodna kwasu 5-amino-3-metylo-4-izoksazolokarboksylowego, sposób jej wytwarzania i zastosowanie